Zobrazeno 1 - 10
of 207
pro vyhledávání: '"Molecular residual disease"'
Autor:
Xinxing Li, Tao Liu, Antonella Bacchiocchi, Mengxing Li, Wen Cheng, Tobias Wittkop, Fernando L Mendez, Yingyu Wang, Paul Tang, Qianqian Yao, Marcus W Bosenberg, Mario Sznol, Qin Yan, Malek Faham, Li Weng, Ruth Halaban, Hai Jin, Zhiqian Hu
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 9, Pp 2188-2209 (2024)
Abstract While whole genome sequencing (WGS) of cell-free DNA (cfDNA) holds enormous promise for detection of molecular residual disease (MRD), its performance is limited by WGS error rate. Here we introduce AccuScan, an efficient cfDNA WGS technolog
Externí odkaz:
https://doaj.org/article/61e8893361234a0aaada760b5863e691
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Melanoma of the uveal tract or uveal melanoma (UM) originates from melanocytes of the eye and is the most common intraocular malignancy in adults. Despite considerable advances in diagnostic procedures and treatments, prognosis remains poor in those
Externí odkaz:
https://doaj.org/article/030773d92bdd41728d93cae95cd71437
Autor:
Youjin Oh, Sung Mi Yoon, Jeeyeon Lee, Joo Hee Park, Soowon Lee, Timothy Hong, Liam Il‐young Chung, Sumedha Sudhaman, Timothy Riddell, Charuta C. Palsuledesai, Michael Krainock, Minetta C. Liu, Young Kwang Chae
Publikováno v:
Thoracic Cancer, Vol 15, Iss 13, Pp 1095-1102 (2024)
Abstract Background Circulating tumor DNA (ctDNA) has emerged as a prognostic and predictive biomarker for detection of minimal residual disease (MRD), monitoring treatment response, and early detection of recurrence in cancer patients. In this study
Externí odkaz:
https://doaj.org/article/2756170525d0413ebe1b183d96a92a3b
Autor:
Song Dong, PhD, Bingfa Yan, PhD, Si-Yang Liu, PhD, Xuan Gao, PhD, Hui-Zhao Hong, MD, Hong-Ji Li, MD, Wei Gao, PhD, Hong-Hong Yan, PhD, Si-Yang Maggie Liu, PhD, Hai-Yan Tu, PhD, Yi Pan, PhD, Qing Zhou, PhD, Xue-Ning Yang, PhD, Xue-Feng Xia, PhD, Xin Yi, PhD, Wen-Zhao Zhong, PhD, Yi-Long Wu, MD, Jia-Tao Zhang, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 6, Iss 1, Pp 100758- (2025)
Introduction: EGFR tyrosine kinase inhibitor (TKI) is the standard adjuvant treatment for patients with stages IB to IIIA EGFR-mutated NSCLC. Nevertheless, adapting this approach to include a molecular residual disease (MRD)-guided de-escalation stra
Externí odkaz:
https://doaj.org/article/53643bd155c048d5bc49ea739a649af6
Autor:
Suyog Jain, Shaheenah Dawood, Viraj Lavingia, Dan Aderka, Esther Tahover, Yao-Yu Hsieh, Mark Temper, Alesya Goldman, Marwan AI. Akasheh, Steve Olsen, Sandra San Hsing, Nisarg Joshi, Hsiao-Yu Jen
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionThe presence of minimal residual disease (MRD) after curative-intent surgery for early-stage cancers is associated with disease recurrence. Circulating tumour deoxyribonucleic acid (ctDNA) has emerged as a promising biomarker for MRD asse
Externí odkaz:
https://doaj.org/article/c91aaac94d5c4fdb9f6f21289320c8f0
Autor:
Mayur Narkhede, Sarah Tomassetti, Madiha Iqbal, Antony Tin, Samuel Rivero-Hinojosa, Giby V. George, Hayley Widden, Ryan Benrud, Meenakshi Malhotra, Angel Rodriguez, Minetta C. Liu
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundA novel approach for molecular residual disease (MRD) detection and treatment monitoring is needed in diffuse large B-cell lymphoma (DLBCL) to identify patients with a poor prognosis. We performed a retrospective evaluation of commercial ct
Externí odkaz:
https://doaj.org/article/275a98f96b254ebebbd094c8182d6f4f
Publikováno v:
Journal of the National Cancer Center, Vol 3, Iss 3, Pp 203-210 (2023)
Detection of minimal/molecular residual disease (MRD) based on ctDNA assay develops from hematological malignancies to solid tumors. Generally, there are two mainstream assays in MRD testing technology: tumor-informed and tumor-agnostic. For colorect
Externí odkaz:
https://doaj.org/article/698d67654ede4255941e38c91a2ccb31
Autor:
Zining Qi, Yi Li, ZhengKun Wang, Xuerong Tan, Yixuan Zhou, Zhendong Li, Weirong Zhao, Xin Zheng, Jicheng Yao, Feng Li, Weifeng Wang, Zhizheng Wang, Fei Pang, Gang Wang, Weiguang Gu
Publikováno v:
Cancer Medicine, Vol 12, Iss 16, Pp 16687-16696 (2023)
Abstract Background Circulating tumor DNA (ctDNA)‐based minimal residual disease (MRD) detection, which can identify disease relapse ahead of radiological imaging, has shown promising performance. The objective of this study was to develop and vali
Externí odkaz:
https://doaj.org/article/2b3c933c044e43afbf67e5f0ffd05caf
Autor:
Rui Fu, Jun Huang, Xiaoru Tian, Chaoyang Liang, Yuanyuan Xiong, Jia‐Tao Zhang, Benyuan Jiang, Song Dong, Yuhua Gong, Wei Gao, Fang Li, Yonglei Shi, Zhentian Liu, Xuan Gao, Rongrong Chen, Wenzhao Zhong, Yi Zhang
Publikováno v:
Molecular Oncology, Vol 17, Iss 5, Pp 825-838 (2023)
Circulating tumor DNA (ctDNA) has potential as a promising biomarker for molecular residual disease (MRD) detection in lung cancer. As the next‐generation sequencing standardized panel for ctDNA detection emerges, its clinical utility needs to be v
Externí odkaz:
https://doaj.org/article/e4f5ea1121974d468711e93147e294cc
Publikováno v:
Medicine Advances, Vol 1, Iss 1, Pp 79-88 (2023)
Abstract The prognostic value of molecular residual disease (MRD) in non‐small cell lung cancer (NSCLC) cases using high‐depth circulating tumor DNA (ctDNA) sequencing has been well documented. The utility of MRD to direct individualized therapy
Externí odkaz:
https://doaj.org/article/ea554e23797148f0bf394ecb8dc1c85e